|
Oncovista Innovative Therapies, Inc (OVIT) |
|
|
|
OVIT's Net Income Growth by Quarter and Year
Oncovista Innovative Therapies, Inc's Net Income results by quarter and year
Select the Comparisons :
|
|
Select the Ratio:
|
|
OVIT Net Income (in millions $) |
FY 2015 |
FY 2014 |
FY 2013 |
FY 2012 |
IV Quarter |
December |
-
|
-1.57
|
-0.38
|
-0.35
|
III Quarter |
September |
-0.33
|
0.23
|
-0.37
|
-0.37
|
II Quarter |
June |
-1.10
|
-0.89
|
-0.26
|
-0.25
|
I Quarter |
March |
-0.28
|
-0.31
|
-0.45
|
-0.66
|
FY |
|
-1.71
|
-2.54
|
-1.46
|
-1.63
|
OVIT Net Income third quarter 2015 Y/Y Growth Comment |
Oncovista Innovative Therapies, Inc in the third quarter 2015 recorded net loss of $ -0.33 millions.
According to the results reported in the third quarter 2015, Oncovista Innovative Therapies, Inc achieved the best Net Income growth in Biotechnology & Pharmaceuticals industry. While Oncovista Innovative Therapies, Inc' s Net Income no change of % ranks overall at the positon no. in the third quarter 2015.
|
OVIT Net Income ( Y/Y Growth %) |
2015
|
2014 |
2013 |
2012 |
IV Quarter |
December |
- |
- |
- |
- |
III Quarter |
September |
- |
- |
- |
- |
II Quarter |
June |
- |
- |
- |
- |
I Quarter |
March |
- |
- |
- |
- |
FY |
|
- |
- |
- |
- |
OVIT Net Income (Quarter on Quarter Growth %) |
2015
|
2014 |
2013 |
2012 |
IV Quarter |
December |
- |
- |
- |
- |
III Quarter |
September |
- |
- |
- |
- |
II Quarter |
June |
- |
- |
- |
- |
I Quarter |
March |
- |
- |
- |
- |
FY (Year on Year) |
|
- |
- |
- |
- |
Net Income Y/Y Growth Statistics |
High |
Average |
Low |
0 % |
0 % |
0 % |
|
|
|
|
Net Income Y/Y Growth Statistics |
High |
Average |
Low |
0 % |
0 % |
0 % |
|
|
|
|
Net Income by Quarter for the Fiscal Years 2012, 2013, 2014, 2015 |
Oncovista Innovative Therapies, Inc's Q/Q Net Income Growth
Net Income Q/Q Growth Statistics |
High |
Average |
Low |
0 % |
0 % |
0 % |
|
|
|
OVIT's III. Quarter Q/Q Net Income Comment |
Although Oncovista Innovative Therapies, Inc in the III. Quarter 2015 admitted net loss of $ -0.33 millions, some analyst mentioned, that current results show recovery compare to the -1.10 millions in the second quarter.
Within Biotechnology & Pharmaceuticals industry Oncovista Innovative Therapies, Inc achieved highest sequential Net Income growth. While Oncovista Innovative Therapies, Inc's Net Income growth quarter on quarter, overall rank is . |
|
|
Net Income Q/Q Growth Statistics |
High |
Average |
Low |
0 % |
0 % |
0 % |
|
|
|
OVIT's III. Quarter Q/Q Net Income Comment |
Even if Oncovista Innovative Therapies, Inc in the III. Quarter 2015 showed net loss of $ -0.33 millions, some analyst mentioned, that current results show recovery compare to the -1.10 millions in the second quarter.
Within Biotechnology & Pharmaceuticals industry Oncovista Innovative Therapies, Inc achieved highest sequential Net Income growth. While Oncovista Innovative Therapies, Inc's Net Income growth quarter on quarter, overall rank is . |
|
Oncovista Innovative Therapies, Inc's 12 Months Net Income Growth Year on Year
Net Income TTM Growth |
12 Months Ending (Sep 30 2015) |
12 Months Ending (Jun 30 2015) |
12 Months Ending (Mar 31 2015) |
12 Months Ending (Dec 31 2014) |
12 Months Ending (Sep 30 2014) |
Cumulative Net Income 12 Months Ending |
$ -3.27 |
$ -2.72 |
$ -2.51 |
$ -2.54 |
$ -1.35 |
Y / Y Net Income Growth (TTM) |
- |
- |
- |
- |
- |
Year on Year Net Income Growth Overall
Ranking |
# |
# |
# |
# |
# |
Seqeuential Net Income Change (TTM) |
- |
- |
- |
- |
- |
Seq. Net Income Growth (TTM) Overall
Ranking |
# |
# |
# |
# |
# |
Cumulative Net Income growth
Comment |
Oncovista Innovative Therapies, Inc' has realized cumulative trailing twelve months net loss of $ -3 millions in the Sep 30 2015 period. The business is detiriorating as the cumulative net loss is getting bigger from $ -2.72 millions in TTM ending quarter Jun 30 2015 and $ -1.944346 millions for the twelve months ending in the quarter Sep 30 2014.
Oncovista Innovative Therapies, Inc achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. . |
Net Income TTM Q/Q Growth Statistics |
High |
Average |
Low |
0 % |
0 % |
0 % |
|
|
|
|
|
Net Income TTM Y/Y Growth Statistics |
High |
Average |
Low |
0 % |
0 % |
0 % |
|
|
|
Net Income TTM Q/Q Growth Company Ranking |
Within: |
No. |
Industry |
# |
Sector |
# |
S&P 500 |
# |
|
Cumulative Net Income growth
Comment |
Oncovista Innovative Therapies, Inc' has realized cumulative trailing twelve months net loss of $ -3 millions in the Sep 30 2015 period. The situation is getting worse as the cumulative net loss is becoming larger from $ -2.72 millions for the period from Jun 30 2015 to Sep 30 2014 and $ -1.944346 millions from the TTM period ending Sep 30 2014 Melissa Larsson told.
Oncovista Innovative Therapies, Inc achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. . |
Net Income TTM Q/Q Growth Statistics |
High |
Average |
Low |
0 % |
0 % |
0 % |
|
|
|
Net Income TTM Y/Y Growth Statistics |
High |
Average |
Low |
0 % |
0 % |
0 % |
|
|
|
Net Income TTM Q/Q Growth Company Ranking |
Within: |
No. |
Industry |
# |
Sector |
# |
S&P 500 |
# |
|